4.2 Polycystic Ovary Syndrome (PCOS) & Hyperandrogenic Disorders
Key Takeaways
Polycystic ovary syndrome (PCOS) is a complex neuroendocrine and metabolic disorder characterized by ovarian thecal cell androgen hypersecretion, accelerated LH pulsatility, and compensatory hyperinsulinemia.
Under the 2003 Rotterdam consensus criteria, diagnosis requires at least two of three cardinal features: ovulatory dysfunction (oligo- or anovulation), clinical and/or biochemical hyperandrogenism, and polycystic ovarian morphology on transvaginal ultrasound (>=20 follicles per ovary measuring 2–9 mm or ovarian volume >=10 mL), after excluding mimickers.
Differential diagnosis requires targeted laboratory exclusions: 17-hydroxyprogesterone to rule out non-classic congenital adrenal hyperplasia (NCCAH), serum prolactin for hyperprolactinemia, TSH for thyroid disease, and rapid virilization workup (total testosterone >200 ng/dL or DHEAS >700 mcg/dL) for androgen-secreting neoplasms.
Metabolic sequelae mandate universal screening with a 2-hour 75g oral glucose tolerance test (OGTT) due to high rates of impaired glucose tolerance and type 2 diabetes, along with lipid profiling, non-alcoholic fatty liver disease (NAFLD) surveillance, and endometrial protection against unopposed estrogen.
Multimodal management prioritizes lifestyle modification (5%–10% weight loss restores ovulation in up to 50% of overweight patients); combined oral contraceptives (COCs) serve as first-line therapy for cycle control and hirsutism; spironolactone provides anti-androgen therapy with strict contraception; and letrozole is the first-line ovulation induction agent for fertility.
Polycystic Ovary Syndrome (PCOS) & Hyperandrogenic Disorders
Polycystic ovary syndrome (PCOS) is the most prevalent endocrine and reproductive disorder among women of reproductive age, affecting approximately 8% to 13% globally. It is a heterogeneous metabolic and neuroendocrine disorder characterized by the interplay of thecal cell androgen hypersecretion, accelerated hypothalamic-pituitary gonadotropin pulsatility, and peripheral insulin resistance with compensatory hyperinsulinemia.
Important
PCOS is fundamentally a diagnosis of exclusion. Clinicians must rule out non-classic congenital adrenal hyperplasia (NCCAH), hyperprolactinemia, thyroid disorders, Cushing syndrome, and androgen-secreting ovarian or adrenal neoplasms before establishing a diagnosis.
Pathophysiology & Neuroendocrine Dysregulation
The pathophysiology of PCOS spans ovarian, neuroendocrine, and systemic metabolic pathways:
- Thecal Cell Hyperactivity: Ovarian theca interna cells constitutively overexpress steroidogenic enzymes, particularly CYP17A1 (17-alpha-hydroxylase and 17,20-lyase), driving excessive conversion of progestins to androstenedione and testosterone.
- Accelerated GnRH Pulsatility: Rapid hypothalamic GnRH pulses favor pituitary gonadotrope synthesis of luteinizing hormone (LH) over follicle-stimulating hormone (FSH). This elevates the circulating LH:FSH ratio (characteristically 2:1 or 3:1).
- Follicular Arrest: Relative FSH deficiency prevents adequate induction of CYP19A1 (aromatase) in granulosa cells. Without sufficient aromatization of androgens to estrogens, follicular development arrests in the preantral and early antral stage (2 to 9 mm), producing chronic anovulation and polycystic ovarian morphology.
- Hyperinsulinemia & Reduced SHBG: Peripheral insulin resistance triggers compensatory hyperinsulinemia. Insulin acts as a co-gonadotropin on thecal insulin and IGF-1 receptors to amplify LH-stimulated androgen production. Concurrently, insulin downregulates hepatic synthesis of sex hormone-binding globulin (SHBG), markedly increasing circulating free, biologically active testosterone.
- Unopposed Estrogen: Peripheral adipose tissue converts androgens into estrone via aromatase. Persistent, non-cyclic estrogen without cyclical progesterone secretory differentiation promotes continuous mitogenic endometrial stimulation, raising the risk of endometrial hyperplasia and type 1 adenocarcinoma.
Diagnostic Criteria: The Rotterdam Consensus
According to the 2003 Rotterdam Consensus, diagnosis requires at least 2 of the following 3 features, after excluding alternative etiologies:
- Ovulatory Dysfunction: Oligo- or anovulation (cycles >35 days, <8 cycles per year, or amenorrhea >=90 days).
- Clinical and/or Biochemical Hyperandrogenism:
- Clinical: Hirsutism quantified by a modified Ferriman-Gallwey (mFG) score of ≥4–6 (2023 International PCOS Guideline; cutoffs vary by ethnicity), severe inflammatory/cystic acne, or androgenetic alopecia.
- Biochemical: Elevated total/free testosterone or Free Androgen Index (FAI = [total testosterone / SHBG] x 100 >5).
- Polycystic Ovarian Morphology (PCOM): Transvaginal ultrasound demonstrating >=20 follicles per ovary measuring 2 to 9 mm throughout the entire ovary, AND/OR an increased ovarian volume >=10 mL in either ovary (excluding dominant follicles >10 mm or corpus luteum). The 2023 International PCOS Guideline also allows an elevated serum anti-Müllerian hormone (AMH) to stand in for ultrasound PCOM in adults.
Note
In adolescents within 8 years of menarche, pelvic ultrasound is not recommended due to physiologic multicystic ovaries. Diagnosis in adolescents requires both ovulatory dysfunction and clinical or biochemical hyperandrogenism.
Rotterdam PCOS Phenotypes
| Phenotype | Features Present | Metabolic Risk Profile |
|---|---|---|
| Phenotype A (Classic / Full) | Hyperandrogenism + Anovulation + PCOM | Highest risk for insulin resistance and metabolic syndrome |
| Phenotype B (Non-PCOM) | Hyperandrogenism + Anovulation | High metabolic risk |
| Phenotype C (Ovulatory) | Hyperandrogenism + PCOM (regular cycles) | Intermediate metabolic risk |
| Phenotype D (Non-Androgenic) | Anovulation + PCOM (normal androgens) | Lowest metabolic risk |
Differential Diagnosis: Excluding Mimickers
- Non-Classic Congenital Adrenal Hyperplasia (NCCAH): Screen with a morning fasting serum 17-hydroxyprogesterone (17-OHP) in the early follicular phase. A value <200 ng/dL rules out 21-hydroxylase deficiency. Levels 200–1,000 ng/dL require cosyntropin (synthetic ACTH) stimulation testing (>1,000 ng/dL confirms NCCAH).
- Hyperprolactinemia: Fasting serum prolactin excludes prolactin-secreting adenomas that suppress GnRH.
- Thyroid Disorders: Serum TSH excludes hypothyroidism, which increases TRH and secondarily elevates prolactin while decreasing SHBG.
- Androgen-Secreting Neoplasms: Suspect with rapid virilization (clitoromegaly, voice deepening, rapid baldness). Total testosterone >200 ng/dL suggests an ovarian tumor (Sertoli-Leydig); DHEAS >700 mcg/dL suggests an adrenal neoplasm. Warrant urgent pelvic ultrasound or adrenal CT/MRI.
- Cushing Syndrome: Screen with 24-hour urinary free cortisol or 1-mg overnight dexamethasone suppression test when clinical stigmata (buffalo hump, moon facies, purple striae >1 cm, proximal muscle weakness) are present.
Metabolic Sequelae & Surveillance Protocols
- Type 2 Diabetes Screening: Up to 35% of individuals with PCOS have impaired glucose tolerance. A mandatory 2-hour 75g oral glucose tolerance test (OGTT) is recommended at baseline (fasting glucose and HbA1c miss over 50% of abnormal cases in PCOS). Repeat every 1 to 3 years.
- Cardiovascular & Lipid Surveillance: Fasting lipid panel every 2 to 3 years. Typical pattern shows high triglycerides (>150 mg/dL), low HDL (<50 mg/dL), and increased small dense LDL particles.
- NAFLD / MASLD: Monitor serum transaminases (ALT/AST) for hepatic steatosis driven by insulin resistance.
- Obstructive Sleep Apnea (OSA): Screen via validated tools (e.g., STOP-BANG), especially in individuals with obesity or daytime fatigue.
- Endometrial Protection: Unopposed estrogen elevates endometrial cancer risk 2- to 6-fold. Evaluate amenorrheic intervals (>3 months) and biopsy patients aged >=45 years or those with persistent abnormal bleeding.
Multimodal Management
- Lifestyle & Weight Optimization: First-line foundation. A 5% to 10% weight loss reduces visceral fat, lowers fasting insulin by 30%–50%, increases SHBG, reduces free testosterone, and restores spontaneous ovulatory cycles in up to 50% of overweight patients.
- Combined Oral Contraceptives (COCs): First-line pharmacotherapy for non-fertility goals. Ethinyl estradiol suppresses LH secretion (decreasing thecal androgens) and boosts hepatic SHBG synthesis. The progestin prevents endometrial hyperplasia. Low-androgenic progestins (norgestimate, desogestrel) or anti-androgenic progestins (drospirenone) are preferred.
- Anti-Androgens: Spironolactone (50–200 mg daily) competitively blocks androgen receptors at the pilosebaceous unit and inhibits 5-alpha reductase. Clinical reduction of hirsutism requires 6 to 9 months of therapy. Safety Warning: Spironolactone is teratogenic (causes feminization of male fetuses) and must never be used without reliable contraception (COCs or LARC).
- Metformin (1,500–2,000 mg daily): Improves insulin sensitivity and hepatic gluconeogenesis in patients with impaired glucose tolerance or metabolic syndrome.
- Ovulation Induction: Letrozole (aromatase inhibitor, 2.5–7.5 mg daily for 5 days starting cycle day 3 or 5) is the first-line agent for infertility in PCOS (superior live-birth and lower multiple gestation rates over clomiphene citrate). Clomiphene citrate remains a second-line SERM alternative.
A 24-year-old female presents with irregular menstrual cycles occurring every 45 to 75 days, severe cystic facial acne, and worsening dark, coarse hair growth along her chin, lower abdomen, and upper back. Her body mass index (BMI) is 31.2 kg/m². Pelvic ultrasonography reveals enlarged ovaries bilaterally, each containing 22 to 24 subcapsular follicles measuring 3 to 8 mm. Serum 17-hydroxyprogesterone is 85 ng/dL, TSH is 1.8 mIU/L, prolactin is 12 ng/mL, and total testosterone is 68 ng/dL (reference range 15–45 ng/dL). According to international evidence-based clinical practice guidelines, which diagnostic test is mandatory to screen for metabolic comorbidity in this patient?
2-hour 75-gram oral glucose tolerance test (OGTT)
Fasting serum insulin level alone
24-hour urinary free cortisol excretion test
Adrenal computed tomography with intravenous contrast
A 28-year-old female with confirmed PCOS presents for follow-up. She has been taking a combined oral contraceptive (ethinyl estradiol 30 mcg / drospirenone 3 mg) consistently for 6 months. While her menstrual cycles are now predictable and monthly, she remains distressed by persistent, coarse chin and submandibular hirsutism. She is sexually active and uses condoms in addition to her oral contraceptive. She does not desire pregnancy. What is the most appropriate next step in pharmacologic management?
Stop the oral contraceptive and start finasteride monotherapy for the hirsutism.
Add spironolactone 50–100 mg daily while continuing her combined oral contraceptive.
Start clomiphene citrate 50 mg on cycle days 3 through 7 to clear androgenic follicles.
Switch to a pill with a more androgenic progestin, such as high-dose levonorgestrel.
A 26-year-old woman presents for evaluation of oligomenorrhea and severe facial hair growth that has developed rapidly over the past 4 months. Physical examination reveals a modified Ferriman-Gallwey score of 18, prominent temporal hair balding, and marked clitoromegaly. Diagnostic laboratory evaluation reveals a serum total testosterone level of 260 ng/dL (reference range 15–45 ng/dL) and a normal DHEAS level of 180 mcg/dL. Urine pregnancy test is negative. Which of the following is the most appropriate next step in clinical management?
Prescribe metformin 500 mg twice daily and re-evaluate total testosterone in 6 months.
Diagnose severe PCOS under Rotterdam criteria and initiate combined oral contraceptives.
Reassure the patient that elevated testosterone is characteristic of anovulation and begin letrozole.
Order urgent transvaginal pelvic ultrasonography to evaluate for an androgen-secreting ovarian neoplasm.
Sections you finish are checked off in the contents.